Younossi Z - Search Results

1

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.

Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Younossi Z, et al. Hepatology. 2013 Dec;58(6):1897-906. doi: 10.1002/hep.26437. Epub 2013 Oct 17. Hepatology. 2013. PMID: 24382638 Clinical Trial.

2

Nonalcoholic fatty liver disease: an agenda for clinical research.

Younossi ZM, Diehl AM, Ong JP. Younossi ZM, et al. Hepatology. 2002 Apr;35(4):746-52. doi: 10.1053/jhep.2002.32483. Hepatology. 2002. PMID: 11915019 Review. No abstract available.

3

Advances in treatment of chronic hepatitis C: 'pegylated' interferons.

Sharieff KA, Duncan D, Younossi Z. Sharieff KA, et al. Among authors: younossi z. Cleve Clin J Med. 2002 Feb;69(2):155-9. doi: 10.3949/ccjm.69.2.155. Cleve Clin J Med. 2002. PMID: 11990646 Free article. Review.

4

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Poynard T, et al. Among authors: younossi z. Hepatology. 2003 Jul;38(1):75-85. doi: 10.1053/jhep.2003.50267. Hepatology. 2003. PMID: 12829989 Clinical Trial.

5

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R. Younossi ZM, et al. J Clin Gastroenterol. 2004 Sep;38(8):705-9. doi: 10.1097/01.mcg.0000135372.10846.2a. J Clin Gastroenterol. 2004. PMID: 15319656

6

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.

Ong JP, Younossi ZM. Ong JP, et al. Cleve Clin J Med. 2004 May;71 Suppl 3:S17-21. doi: 10.3949/ccjm.71.suppl_3.s17. Cleve Clin J Med. 2004. PMID: 15468613 Free article. Review.

7

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T. Younossi ZM, et al. Dig Dis Sci. 2005 May;50(5):970-5. doi: 10.1007/s10620-005-2673-y. Dig Dis Sci. 2005. PMID: 15906777 Clinical Trial.

8

Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery.

Srivastava S, Younossi ZM. Srivastava S, et al. Hepatology. 2005 Aug;42(2):490-2. doi: 10.1002/hep.20782. Hepatology. 2005. PMID: 15977205

9

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. Younossi ZM, et al. Hepatology. 2005 Sep;42(3):665-74. doi: 10.1002/hep.20838. Hepatology. 2005. PMID: 16116632

10

Depression, anemia and health-related quality of life in chronic hepatitis C.

Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM. Dan AA, et al. J Hepatol. 2006 Mar;44(3):491-8. doi: 10.1016/j.jhep.2005.11.046. Epub 2005 Dec 27. J Hepatol. 2006. PMID: 16427157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

773 results

Search Page

Filters